These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 30338639)

  • 1. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Inoue Y; Ueno M; Tanaka Y
    Int J Rheum Dis; 2019 Mar; 22(3):434-442. PubMed ID: 30338639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low additive effect of hydroxychloroquine on Japanese patients with systemic lupus erythematosus taking calcineurin inhibitor.
    Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
    Int J Rheum Dis; 2019 Mar; 22(3):468-472. PubMed ID: 30406967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus.
    Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Kawabe A; Miyazaki Y; Inoue Y; Ueno M; Ohkubo N; Fujita Y; Tanaka Y
    Int J Rheum Dis; 2020 Apr; 23(4):549-558. PubMed ID: 32020727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine Improves the Disease Activity and Allows the Reduction of the Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus.
    Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
    Intern Med; 2019 May; 58(9):1257-1262. PubMed ID: 30626831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Hydroxychloroquine Therapy for Systemic Lupus Erythematosus Patients Depend on Administration Dose.
    Wakiya R; Kameda T; Nakashima S; Shimada H; Fahmy Mansour MM; Kato M; Miyagi T; Kadowaki N; Dobashi H
    Intern Med; 2020 Sep; 59(17):2105-2112. PubMed ID: 32522920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compliance and persistence with hydroxychloroquine in South Korean patients with systemic lupus erythematosus.
    Lee SG; Park EK; Park JH; Kweon SM; Kim YK; Kim GT
    Lupus; 2018 Apr; 27(5):753-761. PubMed ID: 29157178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.
    Hanaoka H; Iida H; Kiyokawa T; Takakuwa Y; Kawahata K
    Clin Rheumatol; 2019 Oct; 38(10):2785-2791. PubMed ID: 31175481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Continuation Rate, Safety and Efficacy of Hydroxychloroquine Treatment in a Retrospective Cohort of Systemic Lupus Erythematosus in a Japanese Municipal Hospital.
    Hosokawa Y; Oiwa H
    Intern Med; 2020 Oct; 59(20):2485-2490. PubMed ID: 32641656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus.
    Vázquez-Otero I; Medina-Cintrón N; Arroyo-Ávila M; González-Sepúlveda L; Vilá LM
    Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32434863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple dose-escalation regimen for hydroxychloroquine-induced hypersensitivity reaction in patients with systemic lupus erythematosus enabled treatment resumption.
    Takamasu E; Yokogawa N; Shimada K; Sugii S
    Lupus; 2019 Oct; 28(12):1473-1476. PubMed ID: 31575325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort.
    Geraldino-Pardilla L; Perel-Winkler A; Miceli J; Neville K; Danias G; Nguyen S; Dervieux T; Kapoor T; Giles J; Askanase A
    Lupus; 2019 Jun; 28(7):862-867. PubMed ID: 31122136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).
    Yokogawa N; Kato Y; Sugii S; Inada S
    Mod Rheumatol; 2012 Apr; 22(2):249-55. PubMed ID: 21842436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
    Kan H; Nagar S; Patel J; Wallace DJ; Molta C; Chang DJ
    Clin Ther; 2016 Mar; 38(3):610-24. PubMed ID: 26907503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
    Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
    Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus.
    Yeon Lee J; Lee J; Ki Kwok S; Hyeon Ju J; Su Park K; Park SH
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):536-542. PubMed ID: 27390146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
    Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
    Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuation of hydroxychloroquine in older patients with systemic lupus erythematosus: a multicenter retrospective study.
    Fernandez-Ruiz R; Bornkamp N; Kim MY; Askanase A; Zezon A; Tseng CE; Belmont HM; Saxena A; Salmon JE; Lockshin M; Buyon JP; Izmirly PM
    Arthritis Res Ther; 2020 Aug; 22(1):191. PubMed ID: 32807233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis.
    Cheng LE; Amoura Z; Cheah B; Hiepe F; Sullivan BA; Zhou L; Arnold GE; Tsuji WH; Merrill JT; Chung JB
    Arthritis Rheumatol; 2018 Jul; 70(7):1071-1076. PubMed ID: 29513931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining maintenance therapy with hydroxychloroquine increases LLDAS achievement rates in individuals with stable systemic lupus erythematosus.
    Yoshida M; Minowa K; Amano H; Asai Y; Yamaji K; Tamura N
    Lupus; 2021 Aug; 30(9):1378-1384. PubMed ID: 33966540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.